Cipla Europe (Cipla) and BioQuiddity have entered into a commercial collaboration, covering the territory of the European Union and certain other European countries, for BioQuiddity’s OneDose ReadyfusOR in regional anaesthetic applications for post-surgical pain management. Cipla intends to launch the CE Marked OneDose ReadyfusOR pre-filled with Ropivacaine under its own label into the German market late this year. The ready-to-use infusion systems are non-electric, ambulatory, and should enable seamless transition between sites of care.
“Cipla is an excellent strategic partner for BioQuiddity and our pre-filled ready-to-use post-surgical pain product candidates,” said Joshua Kriesel, President and Chief Executive Officer, BioQuiddity. “Cipla’s strong commercial record puts them in an outstanding position to detail the OneDose ReadyfusOR’s safety, sterility, and ease of use value proposition objectives.
“We are thrilled to be BioQuiddity’s European commercial partner for the OneDose ReadyfusOR”, said Frank Pieters, Head, Cipla Europe. “Cipla believes that this post-surgical pain product candidate presents a unique opportunity to provide an easy to use, well-tolerated, and efficient regional anaesthesia system that could make savings for healthcare providers and patients.”
EP News Bureau– Mumbai